Terms: = Lymphoma AND Neurokinin AND Treatment
15 results:
1. Multiple-day administration of fosaprepitant combined with tropisetron and olanzapine improves the prevention of nausea and vomiting in patients receiving chemotherapy prior to autologous hematopoietic stem cell transplant: a retrospective study.
Ye P; Pei R; Wang T; Cao J; Zhang P; Chen D; Liu X; Du X; Li S; Tang S; Hu Y; Jiang L; Lu Y
Ann Hematol; 2022 Aug; 101(8):1835-1841. PubMed ID: 35668198
[TBL] [Abstract] [Full Text] [Related]
2. A prospective audit on the use of prophylactic antiemetics and rates of CINV in patients receiving carboplatin AUC≥4 or combination anthracycline-cyclophosphamide.
Lo E; Anderson M; Carroll R; Forgeson G; Isaacs R; Jordan J; Satterthwaite L; Wewala N; Fernando J
N Z Med J; 2021 Apr; 134(1533):33-45. PubMed ID: 33927422
[TBL] [Abstract] [Full Text] [Related]
3. lymphoma Occurring During Pregnancy: Current Diagnostic and Therapeutic Approaches.
Shah MR; Brandt JS; David KA; Evens AM
Curr Oncol Rep; 2020 Aug; 22(11):113. PubMed ID: 32804274
[TBL] [Abstract] [Full Text] [Related]
4. Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin's lymphoma undergoing autologous hematopoietic stem cell transplantation: a phase IIa, multicenter study.
Di Renzo N; Musso M; Scimè R; Cupri A; Perrone T; De Risi C; Pastore D; Guarini A; Mengarelli A; Benedetti F; Mazza P; Capria V; Chiusolo P; Cupelli L; Federico V; Bozzoli V; Messa AR; Codega P; Bonizzoni E; Specchia G
Bone Marrow Transplant; 2020 Nov; 55(11):2114-2120. PubMed ID: 32346078
[TBL] [Abstract] [Full Text] [Related]
5. What are new treatment concepts in systemic itch?
Kremer AE
Exp Dermatol; 2019 Dec; 28(12):1485-1492. PubMed ID: 31452276
[TBL] [Abstract] [Full Text] [Related]
6. Peripheral neuropathy in non-Hodgkin's lymphoma patients receiving vincristine with and without aprepitant/fosaprepitant.
Edwards JK; Bossaer JB; Lewis PO; Sant A
J Oncol Pharm Pract; 2020 Jun; 26(4):809-813. PubMed ID: 31446866
[TBL] [Abstract] [Full Text] [Related]
7. Aprepitant for the treatment of Pruritus in Sézary Syndrome: A Randomized Crossover Clinical Trial.
Zic JA; Straka BT; McGirt LY; Nian H; Yu C; Brown NJ
JAMA Dermatol; 2018 Oct; 154(10):1221-1222. PubMed ID: 30140912
[TBL] [Abstract] [Full Text] [Related]
8. Aprepitant for the treatment of Chronic Refractory Pruritus.
He A; Alhariri JM; Sweren RJ; Kwatra MM; Kwatra SG
Biomed Res Int; 2017; 2017():4790810. PubMed ID: 29057261
[TBL] [Abstract] [Full Text] [Related]
9. Addition of 3-day aprepitant to ondansetron and dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting among patients with diffuse large B cell lymphoma receiving 5-day cisplatin-based chemotherapy.
Abdel-Malek R; Abbas N; Shohdy KS; Ismail M; Fawzy R; Salem DS; Safwat E
J Egypt Natl Canc Inst; 2017 Sep; 29(3):155-158. PubMed ID: 28844591
[TBL] [Abstract] [Full Text] [Related]
10. Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature.
Song JS; Tawa M; Chau NG; Kupper TS; LeBoeuf NR
BMC Cancer; 2017 Mar; 17(1):200. PubMed ID: 28302100
[TBL] [Abstract] [Full Text] [Related]
11. Itch Management: treatments under Development.
Pereira MP; Ständer S
Curr Probl Dermatol; 2016; 50():71-6. PubMed ID: 27578074
[TBL] [Abstract] [Full Text] [Related]
12. Paraneoplastic pruritus presenting with Hodgkin's lymphoma: a case report.
Villafranca JJ; Siles MG; Casanova M; Goitia BT; Domínguez AR
J Med Case Rep; 2014 Sep; 8():300. PubMed ID: 25200537
[TBL] [Abstract] [Full Text] [Related]
13. treatment of pruritus in early-stage hypopigmented mycosis fungoides with aprepitant.
Jiménez Gallo D; Albarrán Planelles C; Linares Barrios M; Fernández Anguita MJ; Márquez Enríquez J; Rodríguez Mateos ME
Dermatol Ther; 2014; 27(3):178-82. PubMed ID: 24517320
[TBL] [Abstract] [Full Text] [Related]
14. The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines.
Muñoz M; González-Ortega A; Coveñas R
Invest New Drugs; 2012 Apr; 30(2):529-40. PubMed ID: 21120581
[TBL] [Abstract] [Full Text] [Related]
15. Substance-P receptors in human primary neoplasms: tumoral and vascular localization.
Hennig IM; Laissue JA; Horisberger U; Reubi JC
Int J Cancer; 1995 Jun; 61(6):786-92. PubMed ID: 7790112
[TBL] [Abstract] [Full Text] [Related]
